NCT03308825View on ClinicalTrials.gov

Safety and Immunogenicity of Fluzone® Quadrivalent and Fluzone® High-Dose, Influenza Vaccines

PHASE4CompletedINTERVENTIONAL
Enrollment

240

Participants

Timeline

Start Date

September 11, 2017

Primary Completion Date

November 22, 2017

Study Completion Date

November 22, 2017

Conditions
InfluenzaFlu
Interventions
BIOLOGICAL

Fluzone Quadrivalent vaccine

0.25 mL, Intramuscular

BIOLOGICAL

Fluzone Quadrivalent vaccine

0.5 mL, Intramuscular

BIOLOGICAL

Fluzone High-Dose vaccine

0.5 mL, Intramuscular

Trial Locations (3)

40004

Sanofi Pasteur Investigational Site 002, Bardstown

51503

Sanofi Pasteur Investigational Site 003, Council Bluffs

70006

Sanofi Pasteur Investigational Site 001, Metairie

All Listed Sponsors
lead

Sanofi Pasteur, a Sanofi Company

INDUSTRY

NCT03308825 - Safety and Immunogenicity of Fluzone® Quadrivalent and Fluzone® High-Dose, Influenza Vaccines | Biotech Hunter | Biotech Hunter